SUSTAINABLE DEVELOPMENT
Innovate. Sustain. Transform.
Save up to 30% on top Physical Sciences & Engineering titles!

In the past 5 years, there has been a tremendous increase in interest regarding diagnosis and management the cardiac involvement in sarcoidosis. This includes new imaging… Read more
SUSTAINABLE DEVELOPMENT
Save up to 30% on top Physical Sciences & Engineering titles!
RB
Dr. Baughman is the Professor of Medicine at the University of Cincinnati. After completing undergraduate training at Yale University, he received his medical degree from Case Western Reserve School of Medicine. He joined the Internal Medicine staff at the University of Cincinnati after completing both an internal medicine residency and fellowship training in pulmonary diseases at the University of Cincinnati. His major research interests include the treatment of sarcoidosis and bronchoalveolar lavage. Along with his long-time collaborator Dr. Elyse Lower, he has developed several novel treatments for sarcoidosis, including methotrexate, thalidomide, leflunomide, and infliximab. Current studies include treatments for sarcoidosis-associated fatigue and pulmonary hypertension due to sarcoidosis. He is on the editorial board of multiple subspecialty journals, and his publications include over 300 original papers mostly regarding various aspects of sarcoidosis and over 70 review articles and/or book chapters. He has edited several books on sarcoidosis and other interstitial lung diseases. He is on the editorial board of several journals, including the American Journal of Respiratory and Critical Care Medicine and Chest. In addition, Dr. Baughman is the recent editor of books on sarcoidosis, interstitial lung disease, and ventilator-associated pneumonia. He has been an active member of the WASOG since its inception and is President Emeritus.
DC
DB
Dr. David Birnie is Vered Chair and Head, Division of Cardiology at the University of Ottawa Heart Institute (UOHI). He was educated in Scotland and received his medical degree from Glasgow University in 1990. His clinical focus is on all aspects of cardiac electrophysiology, including ablation of complex arrhythmia and implantation and follow-up of device therapy. He also has a major clinical interest in cardiac sarcoidosis and coinitiated (in 2008) and still coleads Canada’s first dedicated cardiac sarcoidosis clinic. He is the cochair of the HRS guidelines on the diagnosis and management of cardiac sarcoidosis (published in 2014 and update due in 2026). Also, he is leading the first multicenter, multinational treatment trial for cardiac sarcoidosis (CHASM-CS-RCT). His major ongoing research interests are cardiac sarcoidosis, selection and optimization of CRT for heart failure patients, and investigating optimal strategies for complication reduction around EP procedures. In 2020 he was elected to the executive committee of the World Association of Sarcoidosis (WASOG).